Capitan Orthopedics, Inc. Closes Oversubscribed Seed Round
Capitan Orthopedics, Inc. has successfully closed its oversubscribed Seed round, raising a total of $4.1 million. The funds will be used to continue the development of their innovative SupraSpacer™ implant for treating irreparable rotator cuff tears, with plans for an in-human clinical trial starting in Q1 2027. The company has also received FDA Breakthrough Device Designation, showcasing confidence in its technology’s potential impact.
GRAND RAPIDS, Mich., Aug. 18, 2026 /PRNewswire/ — Capitan Orthopedics, Inc. (https://capitanortho.com/) announced today that it has closed its oversubscribed Seed round, bringing its total capital raised to date to $4.1 million. Chance W. Leonard, CEO of Capitan Orthopedics, Inc.,…